Suche
Mein Konto
CureVac: Financial crisis and threatened takeover by BioNTech!
CureVac, based in Tübingen, reports Q2 and H1 2025 financial results; BioNTech plans share takeover.
CureVac: Financial crisis and threatened takeover by BioNTech!
Today, August 15, 2025, CureVac's latest financial results are a topic of conversation in the biotech scene. The Tübingen-based company, known for its innovations in mRNA technology, recently published its financial results for the second quarter and first half of 2025. Loud TradingView There is a significant decline in both sales and losses compared to the previous year.
In the second quarter, CureVac generated sales of 1.2 million euros, a decrease of 91% compared to 2024. In the first half of the year, sales totaled 2.1 million euros, a worrying decline of 92%. Despite these challenges, according to the latest report, the company has cash and equivalents of €392.7 million as of June 30, 2025, ensuring a solid cash runway through 2028.
Strategic steps and future developments
A particularly important point is the agreement to resolve all patent disputes with Pfizer/BioNTech in the USA. This could open up new opportunities for CureVac as BioNTech also plans to acquire all of CureVac's shares. These strategic steps point to an exciting phase in the company's development.
The European Medicines Agency (EMA) has also approved a clinical trial (CTA) for CVHNLC. CVGBM glioblastoma data from the phase 1 study are also expected in the planned time frame for the second half of 2025. Despite the financial challenges, the company remains active in its research efforts.
CureVac's financial challenges
The operational losses cannot be overlooked: in the second quarter the loss was 61.7 million euros, while the loss in the first half of the year totaled 116.5 million euros. These figures show that CureVac, despite its high potential, is facing significant financial difficulties. The net financial result for the second quarter is 1.7 million euros, which also represents a decrease compared to the previous year.
Internationally, the company has offices in the Netherlands, Belgium, Switzerland and the USA, underscoring its global reach and importance. It remains to be seen how the corporate culture and innovative strength will develop in times of financial uncertainty.
In a completely different area, spring brings a breath of fresh air to Jackery. The brand is currently offering discounts on various products, which is driving sales enthusiasm. The company specializes in producing portable energy solutions that are not only practical but also sustainable. For more information, interested readers can take a look here Jackery.
While the biotech industry has its ups and downs, it is important to keep a close eye on developments and always keep your finger on the pulse. Nuremberg proves to be a hotspot for exciting news and developments that influence both the economic and social structure.